Ruthenium complexes with abiraterone acetate as antiproliferative agents.

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Inorganic Chemistry

Background:

• Development of novel multimodal anticancer agents is crucial for overcoming drug resistance and improving therapeutic efficacy.
• Ruthenium complexes and abiraterone acetate possess distinct antitumor properties.
• Combining these agents offers a synergistic approach to cancer treatment.

Purpose of the Study:

• To synthesize and characterize novel ruthenium complexes conjugated with abiraterone acetate.
• To evaluate the antiproliferative activity and mechanism of action of these novel compounds against cancer cells.
• To assess the potential of these dual-action agents as next-generation anticancer therapeutics.

Main Methods:

• Synthesis of ruthenium complexes conjugated with abiraterone acetate.
• In vitro antiproliferative assays against various cancer cell lines and primary fibroblasts.
• Real-time cell analysis to determine dose-dependent effects on cell proliferation.
• Flow cytometry to investigate the mechanism of cell death, specifically apoptosis induction.

Main Results:

• The synthesized ruthenium-abiraterone acetate conjugates exhibited significant antiproliferative activity against cancer cells.
• A notable selectivity was observed, with reduced toxicity towards primary fibroblasts.
• The compound dichlorido(η⁶-p-cymene)(abiraterone acetate)ruthenium(II) demonstrated enhanced antiproliferation compared to abiraterone acetate alone.
• Flow cytometry confirmed that the most active compound effectively induced apoptosis in cancer cells.

Conclusions:

• Ruthenium complexes conjugated with abiraterone acetate represent promising multimodal anticancer agents.
• The enhanced efficacy and apoptosis-inducing properties highlight their potential for clinical development.
• This dual-action strategy offers a novel therapeutic avenue for cancer treatment.